AstraZeneca's oral relaxin drug AZD5462 hits its HFpEF endpoint but narrowly misses in HFrEF in the Phase 2b LUMINARA heart ...
CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to ...
Lilly's Mounjaro wins a CV nod, Teva buys BioXcel's assets, AusperBio raises $120M and Samsung Biologics preps a $2.2B raise.
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer.
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a ...
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed ...
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in ...
Fifth Circuit rejects PhRMA's challenge to Medicare drug-price negotiation, ending pharma's first wave of IRA litigation.
After lengthy consideration, a DC federal judge on Monday rejected Merck’s challenge to Medicare drug price ...
MassBio report shows MA biopharma jobs fell 3.1%, NIH awards dropped 6%, while China's drug pipeline grew 36% in 2025, ...
Metriport raises $26M Series A led by Matrix to help doctors retrieve and prioritize patient data from across health systems.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results